Display options
Cite
Ruuskanen MO, Åberg F, Männistö V, et al. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes. 2021;13(1):1-22doi: 10.1080/19490976.2021.1888673.
Ruuskanen, M. O., Åberg, F., Männistö, V., Havulinna, A. S., Méric, G., Liu, Y., Loomba, R., Vázquez-Baeza, Y., Tripathi, A., Valsta, L. M., Inouye, M., Jousilahti, P., Salomaa, V., Jain, M., Knight, R., Lahti, L., & Niiranen, T. J. (2021). Links between gut microbiome composition and fatty liver disease in a large population sample. Gut microbes, 13(1), 1-22. https://doi.org/10.1080/19490976.2021.1888673
Ruuskanen, Matti O, et al. "Links between gut microbiome composition and fatty liver disease in a large population sample." Gut microbes vol. 13,1 (2021): 1-22. doi: https://doi.org/10.1080/19490976.2021.1888673
Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes. 2021 Jan-Dec;13(1):1-22. doi: 10.1080/19490976.2021.1888673. PMID: 33651661; PMCID: PMC7928040.
Copy Download .nbib Format: NLM
Share it on

Gut Microbes. 2021 Jan-Dec;13(1):1-22. doi: 10.1080/19490976.2021.1888673.

Links between gut microbiome composition and fatty liver disease in a large population sample.

Gut microbes

Matti O Ruuskanen, Fredrik Åberg, Ville Männistö, Aki S Havulinna, Guillaume Méric, Yang Liu, Rohit Loomba, Yoshiki Vázquez-Baeza, Anupriya Tripathi, Liisa M Valsta, Michael Inouye, Pekka Jousilahti, Veikko Salomaa, Mohit Jain, Rob Knight, Leo Lahti, Teemu J Niiranen

Affiliations

  1. Department of Internal Medicine, University of Turku, Turku, Finland.
  2. Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland.
  3. Transplantation and Liver Surgery Clinic, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  4. Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
  5. Department of Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.
  6. Department of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  7. Institute for Molecular Medicine Finland, FIMM - HiLIFE, Helsinki, Finland.
  8. Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  9. Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  10. Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
  11. Department of Medicine, NAFLD Research Center, La Jolla, CA, USA.
  12. Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  13. Center for Microbiome Innovation, Jacobs School of Engineering, University of California San Diego, La Jolla, CA, USA.
  14. Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
  15. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
  16. Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA.
  17. Department of Public Health and Primary Care, Cambridge University, Cambridge, UK.
  18. Department of Pharmacology, University of California San Diego, La Jolla, California, USA.
  19. Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA.
  20. Department of Computer Science & Engineering, University of California San Diego, La Jolla, California, USA.
  21. Deparment of Computing, University of Turku, Turku, Finland.
  22. Division of Medicine, Turku University Hospital, Turku, Finland.

PMID: 33651661 PMCID: PMC7928040 DOI: 10.1080/19490976.2021.1888673

Abstract

Fatty liver disease is the most common liver disease in the world. Its connection with the gut microbiome has been known for at least 80 y, but this association remains mostly unstudied in the general population because of underdiagnosis and small sample sizes. To address this knowledge gap, we studied the link between the Fatty Liver Index (FLI), a well-established proxy for fatty liver disease, and gut microbiome composition in a representative, ethnically homogeneous population sample of 6,269 Finnish participants. We based our models on biometric covariates and gut microbiome compositions from shallow metagenome sequencing. Our classification models could discriminate between individuals with a high FLI (≥60, indicates likely liver steatosis) and low FLI (<60) in internal cross-region validation, consisting of 30% of the data not used in model training, with an average AUC of 0.75 and AUPRC of 0.56 (baseline at 0.30). In addition to age and sex, our models included differences in 11 microbial groups from class

Keywords: Metagenomics; fatty liver; fatty liver index; human gut; population sample

References

  1. Nat Med. 2018 Oct;24(10):1526-1531 - PubMed
  2. BMC Genomics. 2016 Oct 21;17(1):819 - PubMed
  3. Nature. 2014 Sep 4;513(7516):59-64 - PubMed
  4. Hepatology. 2016 Jul;64(1):73-84 - PubMed
  5. Cell. 2014 Nov 6;159(4):789-99 - PubMed
  6. Nat Med. 2018 Oct;24(10):1532-1535 - PubMed
  7. Nat Biotechnol. 2020 Sep;38(9):1079-1086 - PubMed
  8. World J Gastroenterol. 2014 Jul 14;20(26):8393-406 - PubMed
  9. Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10 - PubMed
  10. Bioinformatics. 2014 Jul 15;30(14):2068-9 - PubMed
  11. Front Microbiol. 2018 Jun 05;9:1138 - PubMed
  12. Cell Metab. 2017 May 2;25(5):1054-1062.e5 - PubMed
  13. PLoS One. 2015 Mar 17;10(3):e0120443 - PubMed
  14. Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4 - PubMed
  15. Microbiome. 2014 May 05;2:15 - PubMed
  16. Nature. 2020 Mar;579(7800):586-591 - PubMed
  17. PeerJ. 2019 Oct 11;7:e7755 - PubMed
  18. Nat Biotechnol. 2018 Nov;36(10):996-1004 - PubMed
  19. mSystems. 2018 Nov 13;3(6): - PubMed
  20. Gut Microbes. 2020 May 3;11(3):569-580 - PubMed
  21. PLoS One. 2013 Apr 22;8(4):e61217 - PubMed
  22. Hepatology. 2019 Oct;70(4):1457-1469 - PubMed
  23. Nat Ecol Evol. 2018 Jun;2(6):936-943 - PubMed
  24. Sci Rep. 2020 Feb 17;10(1):2771 - PubMed
  25. Syst Appl Microbiol. 2006 Jun;29(4):292-9 - PubMed
  26. Gastroenterology. 2020 May;158(7):1999-2014.e1 - PubMed
  27. Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):643-648 - PubMed
  28. Gut. 2020 Jul;69(7):1258-1268 - PubMed
  29. Ann Hepatol. 2019 Nov - Dec;18(6):796-803 - PubMed
  30. PeerJ. 2017 Aug 30;5:e3720 - PubMed
  31. World J Hepatol. 2018 Aug 27;10(8):530-542 - PubMed
  32. Nucleic Acids Res. 2018 Jan 4;46(D1):D633-D639 - PubMed
  33. Front Microbiol. 2017 Nov 15;8:2224 - PubMed
  34. Genome Res. 2016 Dec;26(12):1721-1729 - PubMed
  35. Nat Biotechnol. 2020 Jun;38(6):685-688 - PubMed
  36. Sci Rep. 2018 Jul 27;8(1):11356 - PubMed
  37. Aliment Pharmacol Ther. 2015 Feb;41(4):406-7 - PubMed
  38. Nat Commun. 2019 Mar 29;10(1):1406 - PubMed
  39. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):805-10 - PubMed
  40. Microorganisms. 2019 Jan 13;7(1): - PubMed
  41. Hepatology. 2020 Aug;72(2):470-485 - PubMed
  42. Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3 - PubMed
  43. Hepatology. 2018 Jul;68(1):234-247 - PubMed
  44. Cell Mol Life Sci. 2019 Apr;76(8):1541-1558 - PubMed
  45. Bioinformatics. 2020 Jul 1;36(13):4088-4090 - PubMed
  46. G3 (Bethesda). 2017 Oct 5;7(10):3459-3468 - PubMed
  47. Nat Methods. 2012 Mar 04;9(4):357-9 - PubMed
  48. J Hosp Infect. 2017 Oct;97(2):153-155 - PubMed
  49. Gastroenterology. 2011 Mar;140(3):976-86 - PubMed
  50. Sci Rep. 2015 Feb 03;5:8096 - PubMed
  51. BMC Biol. 2019 Oct 28;17(1):83 - PubMed
  52. Bioinformatics. 2017 Jan 1;33(1):145-147 - PubMed
  53. Scand J Soc Med Suppl. 1989;40:1-48 - PubMed
  54. Int J Epidemiol. 2018 Jun 1;47(3):696-696i - PubMed
  55. Eur J Public Health. 2015 Jun;25(3):539-46 - PubMed
  56. Medicine (Baltimore). 2015 Oct;94(40):e1682 - PubMed
  57. Elife. 2017 Feb 15;6: - PubMed
  58. Elife. 2020 Dec 29;9: - PubMed
  59. Int J Endocrinol. 2018 Mar 22;2018:4095789 - PubMed
  60. Nutr Metab Cardiovasc Dis. 2012 Jun;22(6):471-6 - PubMed
  61. Front Microbiol. 2016 Jun 15;7:925 - PubMed
  62. BMC Med. 2018 Aug 13;16(1):130 - PubMed
  63. Hepatology. 2012 Jun;55(6):2005-23 - PubMed
  64. Annu Rev Physiol. 2016;78:181-205 - PubMed
  65. Hepatology. 2003 Apr;37(4):917-23 - PubMed
  66. Hepatology. 2016 Jul;64(1):19-22 - PubMed
  67. Genome Biol. 2019 Oct 31;20(1):226 - PubMed
  68. Hepatology. 2009 Jun;49(6):1877-87 - PubMed
  69. Cell Metab. 2019 Oct 1;30(4):675-688.e7 - PubMed
  70. BMC Gastroenterol. 2006 Nov 02;6:33 - PubMed
  71. Eur J Nutr. 2020 Aug;59(5):1845-1858 - PubMed
  72. Eur J Nutr. 2018 Apr;57(3):861-876 - PubMed
  73. J Clin Med. 2019 Jul 24;8(8): - PubMed
  74. Brief Bioinform. 2019 Jul 19;20(4):1085-1093 - PubMed
  75. Hepat Mon. 2018 Oct;18(10): - PubMed
  76. Nutrients. 2020 Jan 16;12(1): - PubMed
  77. Hepatology. 2013 Feb;57(2):601-9 - PubMed
  78. Liver Int. 2014 Jul;34(6):e111-7 - PubMed
  79. Metabolism. 2017 Jul;72:94-108 - PubMed
  80. Nat Med. 2018 Apr 10;24(4):392-400 - PubMed
  81. Biol Lett. 2014 Feb 12;10(2):20131037 - PubMed
  82. Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297 - PubMed
  83. PLoS One. 2017 Oct 9;12(10):e0186216 - PubMed
  84. Nat Commun. 2020 Nov 18;11(1):5886 - PubMed
  85. Nat Rev Endocrinol. 2019 May;15(5):261-273 - PubMed

Publication Types

Grant support